MA42341B2 - Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale - Google Patents

Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale

Info

Publication number
MA42341B2
MA42341B2 MA42341A MA42341A MA42341B2 MA 42341 B2 MA42341 B2 MA 42341B2 MA 42341 A MA42341 A MA 42341A MA 42341 A MA42341 A MA 42341A MA 42341 B2 MA42341 B2 MA 42341B2
Authority
MA
Morocco
Prior art keywords
preparation
protein kinase
kinase inhibitor
medical use
mesomer
Prior art date
Application number
MA42341A
Other languages
English (en)
French (fr)
Other versions
MA42341A1 (fr
Inventor
Lei Yin
Wenjian Liu
Heng Li
Dianxi Zhu
Original Assignee
Gan&Lee Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58796287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42341(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan&Lee Pharmaceuticals filed Critical Gan&Lee Pharmaceuticals
Publication of MA42341A1 publication Critical patent/MA42341A1/fr
Publication of MA42341B2 publication Critical patent/MA42341B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
MA42341A 2015-11-30 2016-11-28 Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale MA42341B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510856641.1A CN106810536A (zh) 2015-11-30 2015-11-30 一种蛋白激酶抑制剂及其制备方法和医药用途
PCT/CN2016/107455 WO2017092635A1 (zh) 2015-11-30 2016-11-28 一种蛋白激酶抑制剂及其制备方法和医药用途

Publications (2)

Publication Number Publication Date
MA42341A1 MA42341A1 (fr) 2018-06-29
MA42341B2 true MA42341B2 (fr) 2021-05-31

Family

ID=58796287

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42341A MA42341B2 (fr) 2015-11-30 2016-11-28 Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale

Country Status (21)

Country Link
US (2) US11091476B2 (enExample)
EP (1) EP3385262B1 (enExample)
JP (2) JP6921101B2 (enExample)
KR (1) KR20180083421A (enExample)
CN (3) CN106810536A (enExample)
AU (1) AU2016365366B2 (enExample)
BR (1) BR112018010879A2 (enExample)
CA (1) CA3002884A1 (enExample)
CO (1) CO2018005854A2 (enExample)
DK (1) DK3385262T3 (enExample)
ES (1) ES2928169T3 (enExample)
HU (1) HUE060152T2 (enExample)
IL (1) IL259711B (enExample)
MA (1) MA42341B2 (enExample)
MX (1) MX387207B (enExample)
PH (1) PH12018550049A1 (enExample)
PT (1) PT3385262T (enExample)
RU (1) RU2749437C2 (enExample)
UA (1) UA124001C2 (enExample)
WO (1) WO2017092635A1 (enExample)
ZA (1) ZA201803531B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN111386272B (zh) 2017-10-27 2023-01-06 费森尤斯卡比肿瘤学有限公司 一种改进的瑞博西尼及其盐的制备方法
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
WO2019170055A1 (zh) * 2018-03-05 2019-09-12 上海海和药物研究开发有限公司 具有cdk4/6激酶抑制活性的化合物、其药用组合物和用途
US20220079944A1 (en) * 2019-01-29 2022-03-17 Beta Pharma, Inc. 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
AR119184A1 (es) * 2019-06-21 2021-12-01 Gan & Lee Pharmaceuticals Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas
WO2020253865A1 (zh) 2019-06-21 2020-12-24 甘李药业股份有限公司 Cdk4/6抑制剂、及其盐和中间体的制备方法
CN116113628B (zh) * 2020-08-31 2026-07-17 甘李药业山东有限公司 一种含cdk4/6抑制剂的药物组合物
EP4214213A1 (en) * 2020-09-21 2023-07-26 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
IL316942A (en) * 2020-12-18 2025-01-01 Prelude Therapeutics Inc CDK inhibitors and their use as drugs
CN112390793B (zh) * 2021-01-19 2021-04-27 中国药科大学 Cdk6/dyrk2双靶点抑制剂及其制备方法和应用
CN117222636B (zh) * 2021-04-12 2026-06-23 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物
WO2022242563A1 (zh) * 2021-05-17 2022-11-24 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
CN118119393A (zh) * 2021-09-14 2024-05-31 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
CN118339157A (zh) * 2021-12-24 2024-07-12 江苏恒瑞医药股份有限公司 氢化吲哚类化合物、其制备方法及其在医药上的应用
CN115093397B (zh) * 2022-06-07 2023-09-05 自贡市第三人民医院 一种用于治疗肿瘤的化合物、合成方法及应用
WO2024051717A1 (zh) * 2022-09-08 2024-03-14 上海深势唯思科技有限责任公司 作为plk1抑制剂的化合物及其制备方法和用途
WO2024066986A1 (zh) * 2022-09-30 2024-04-04 楚浦创制（武汉）医药科技有限公司 2-氨基嘧啶类化合物及其应用、药用组合物
CN121270553B (zh) * 2025-10-31 2026-05-15 广西医科大学第二附属医院(广西医科大学第二临床医学院) 一种抗肿瘤化合物、抗肿瘤制剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
PL357099A1 (en) 2000-02-07 2004-07-12 Abbott Gmbh & Co.Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
NZ534069A (en) * 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
WO2005076854A2 (en) * 2004-02-04 2005-08-25 Smithkline Beecham Corporation Pyrimidinone compounds useful as kinase inhibitors
EA200870217A1 (ru) 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
HRP20170317T1 (hr) * 2008-02-15 2017-04-21 Rigel Pharmaceuticals, Inc. Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
KR101368079B1 (ko) * 2008-05-16 2014-03-14 에프. 호프만-라 로슈 아게 Ｊｎｋ 의 억제제
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US20130310340A1 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2909194A1 (en) * 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
SG11202001498QA (en) 2017-09-05 2020-03-30 Blackthorn Therapeutics Inc Vasopressin receptor antagonists and products and methods related thereto
CN117222636B (zh) 2021-04-12 2026-06-23 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物

Also Published As

Publication number Publication date
EP3385262A4 (en) 2019-06-19
MX2018006370A (es) 2018-09-24
RU2018122864A3 (enExample) 2020-03-17
US11787801B2 (en) 2023-10-17
RU2749437C2 (ru) 2021-06-10
CN108290864A (zh) 2018-07-17
BR112018010879A2 (pt) 2018-11-21
JP2021138737A (ja) 2021-09-16
DK3385262T3 (da) 2022-10-10
AU2016365366A1 (en) 2018-05-17
PH12018550049A1 (en) 2018-10-29
US20210371418A1 (en) 2021-12-02
JP2019500413A (ja) 2019-01-10
US11091476B2 (en) 2021-08-17
CN108290864B (zh) 2022-05-10
PT3385262T (pt) 2022-10-18
CA3002884A1 (en) 2017-06-08
JP6921101B2 (ja) 2021-08-18
IL259711A (en) 2018-07-31
IL259711B (en) 2022-08-01
HUE060152T2 (hu) 2023-02-28
MA42341A1 (fr) 2018-06-29
UA124001C2 (uk) 2021-07-07
ES2928169T3 (es) 2022-11-15
RU2018122864A (ru) 2020-01-13
US20200165239A1 (en) 2020-05-28
CN113956238A (zh) 2022-01-21
WO2017092635A1 (zh) 2017-06-08
EP3385262A1 (en) 2018-10-10
KR20180083421A (ko) 2018-07-20
CN106810536A (zh) 2017-06-09
AU2016365366B2 (en) 2021-03-04
MX387207B (es) 2025-03-18
CN113956238B (zh) 2023-07-14
EP3385262B1 (en) 2022-07-13
CO2018005854A2 (es) 2018-06-20
ZA201803531B (en) 2021-10-27

Similar Documents

Publication Publication Date Title
MA42341A1 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
MA52948B1 (fr) Composés
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
BR112018011475A2 (pt) compostos e métodos para modulação de quinase e indicação para a mesma
PH12016501440A1 (en) Novel heterocyclic compounds
MA56553B1 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
EA201591291A1 (ru) Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
BR112022008786A2 (pt) Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose
MA41607B1 (fr) Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
MA40302A1 (fr) Dérivés de carbazole
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
EP3473625A4 (en) METHOD FOR PRODUCING A CHIRAL PYRROLOPYRIMIDINE COMPOUND
MA39335A1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
MX2021013576A (es) Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo.
MA39983B1 (fr) Dérivés de carboxamide
JOP20200263B1 (ar) مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين d1
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
FR3064634B1 (fr) Derives acryliques de 1 :4, 3 :6 dianhydrohexitol
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MA50093B1 (fr) Composé pentacyclique